Challenges When Outsourcing Viral Safety Services

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter 06-02-2021
Volume 16
Issue 6

Assessing biosafety using NGS-based tests requires a continuum of skills in molecular biology, biocomputing, virology, and quality systems.

Eugene/Stock.adobe.com

Eugene/Stock.adobe.com

Nowadays, many biopharmaceutical operations are outsourced, from R&D to regulatory-driven testing services. These outsourcing activities require a network of partners working hand-in-hand, as a global ecosystem, to bring new and critical medicines to patients in need. Biopharmaceutical companies are increasingly outsourcing to contract research organizations (CROs) and contract manufacturing organizations (CMOs) to not only keep pace with market demands, but also enable rapid expansion of development and manufacturing capabilities, source partners for innovative early stage R&D programs, and achieve greater cost efficiency in resource and expertise utilization.

Read this article in BioPharm International’s Partnerships for Outsourcing May 2021 eBook.

About the authors

Laurent Lafferrère, PhD, is chief operating officer, and Audrey Brussel*, PhD, audrey.brussel@pathoquest.com, is Viral Safety leader; both are at PathoQuest.

*To whom all correspondence should be addressed.

Recent Videos
Behind the Headlines episode 6
Drug Digest: Is Our Understanding of Stability Changing
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Related Content